insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
Company profile
Ticker
INSM
Exchange
Website
CEO
William Lewis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Adrestia Therapeutics Inc. • Celtrix Pharmaceuticals, Inc. • Insmed Gene Therapy LLC • Insmed Limited • Insmed Holdings Limited • Insmed Innovation UK Limited • Insmed Ireland Limited • Insmed Netherlands Holdings B.V. • Insmed Netherlands B.V. • Insmed Germany GmbH ...
IRS number
541972729
INSM stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
8-K
Other Events
11 Mar 24
8-K
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
22 Feb 24
424B5
Prospectus supplement for primary offering
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
5 Jan 24
8-K
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
26 Oct 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Regulation FD Disclosure
5 Sep 23
Transcripts
INSM
Earnings call transcript
2023 Q4
22 Feb 24
INSM
Earnings call transcript
2023 Q3
26 Oct 23
INSM
Earnings call transcript
2023 Q2
3 Aug 23
INSM
Earnings call transcript
2023 Q1
4 May 23
INSM
Earnings call transcript
2023 Q1
4 May 23
INSM
Earnings call transcript
2022 Q4
23 Feb 23
INSM
Earnings call transcript
2022 Q3
27 Oct 22
INSM
Earnings call transcript
2022 Q2
5 Aug 22
INSM
Earnings call transcript
2022 Q1
7 May 22
INSM
Earnings call transcript
2021 Q4
17 Feb 22
Latest ownership filings
4
William Lewis
29 Feb 24
4
MELVIN MD SHAROKY
29 Feb 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
16 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
Martina M.D. Flammer
12 Jan 24
4
Roger Adsett
12 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 487.11 mm | 487.11 mm | 487.11 mm | 487.11 mm | 487.11 mm | 487.11 mm |
Cash burn (monthly) | 41.92 mm | (no burn) | 52.80 mm | 60.16 mm | 45.44 mm | 42.38 mm |
Cash used (since last report) | 291.13 mm | n/a | 366.63 mm | 417.79 mm | 315.58 mm | 294.31 mm |
Cash remaining | 195.99 mm | n/a | 120.48 mm | 69.33 mm | 171.53 mm | 192.80 mm |
Runway (months of cash) | 4.7 | n/a | 2.3 | 1.2 | 3.8 | 4.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 220 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | William Lewis | Common Stock | Option exercise | Acquire M | Yes | No | 12.58 | 50,000 | 629.00 k | 50,500 |
28 Feb 24 | William Lewis | Stock Option Common Stock | Option exercise | Acquire M | Yes | No | 12.58 | 50,000 | 629.00 k | 0 |
28 Feb 24 | Sharoky Melvin MD | Common Stock | Gift | Acquire G | Yes | No | 0 | 1,200 | 0.00 | 4,699 |
28 Feb 24 | Sharoky Melvin MD | Common Stock | Gift | Acquire G | Yes | No | 0 | 1,200 | 0.00 | 3,000 |
28 Feb 24 | Sharoky Melvin MD | Common Stock | Gift | Acquire G | Yes | No | 0 | 1,200 | 0.00 | 4,283 |
28 Feb 24 | Sharoky Melvin MD | Common Stock | Gift | Dispose G | No | No | 0 | 3,600 | 0.00 | 295,015 |
12 Jan 24 | Roger Adsett | Common Stock | Sell | Dispose S | No | Yes | 28.63 | 5,251 | 150.34 k | 148,559 |
12 Jan 24 | Martina M.D. Flammer | Common Stock | Sell | Dispose S | No | Yes | 28.63 | 4,667 | 133.62 k | 106,898 |
10 Jan 24 | Roger Adsett | Common Stock | Sell | Dispose S | No | Yes | 28.9 | 3,536 | 102.19 k | 153,810 |
9 Jan 24 | Roger Adsett | Common Stock | Sell | Dispose S | No | No | 29.25 | 3,837 | 112.23 k | 157,346 |
News
Barclays Maintains Overweight on Insmed, Raises Price Target to $40
11 Apr 24
Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target
1 Apr 24
On March 8, Insmed Received Notice Of Exercise By Astrazeneca AB Of Its Second And Final Option Under License Agreement, Dated Oct 4, 2016
11 Mar 24
Guggenheim Maintains Buy on Insmed, Raises Price Target to $54
27 Feb 24
UBS Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $46
27 Feb 24
Press releases
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
25 Apr 24
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5 Apr 24
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
27 Mar 24
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
22 Feb 24
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
8 Feb 24